Title |
Current management of parainfluenza pneumonitis in immunocompromised patients: a review
|
---|---|
Published in |
Infection and Drug Resistance, August 2012
|
DOI | 10.2147/idr.s25874 |
Pubmed ID | |
Authors |
Ann R Falsey |
Abstract |
Parainfluenza viruses (PIV) are common respiratory viruses that belong to the Paramyxoviridae family. PIV infection can lead to a wide variety of clinical syndromes ranging from mild upper respiratory illness to severe pneumonia. Severe disease can be seen in elderly or chronically ill persons and may be fatal in persons with compromised immune systems, particularly children with severe combined immunodeficiency disease syndrome and hematopathic stem cell transplant recipients. At present, there are no licensed antiviral agents for the treatment of PIV infection. Aerosolized or systemic ribavirin in combination with intravenous gamma globulin has been reported in small, uncontrolled series and case reports of immunocompromised patients. A number of agents show antiviral activity in vitro and in animals, but none are currently approved for human use. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | 4% |
United Kingdom | 1 | 2% |
Unknown | 47 | 94% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Other | 6 | 12% |
Researcher | 6 | 12% |
Student > Ph. D. Student | 5 | 10% |
Student > Doctoral Student | 4 | 8% |
Professor > Associate Professor | 4 | 8% |
Other | 12 | 24% |
Unknown | 13 | 26% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 18 | 36% |
Agricultural and Biological Sciences | 6 | 12% |
Biochemistry, Genetics and Molecular Biology | 5 | 10% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 4% |
Computer Science | 2 | 4% |
Other | 5 | 10% |
Unknown | 12 | 24% |